April 29, 2025 • By Sandoz International GmbH

Sandoz, a global leader in generic and biosimilar medicines, has signed a collaboration agreement with Shanghai Henlius Biotech to commercialize a biosimilar of the oncology therapy ipilimumab. The agreement is worth up to $301 million and targets $2.5 billion in net sales. Sandoz will have exclusive commercial rights in several countries, including the US, Europe, and Japan. The reference medicine, ipilimumab, is used to treat various types of cancer, and its core sequence patent has expired in the US and will expire in the EU by February 2026. This partnership aims to increase patient access to affordable cancer treatments and drive the long-term sustainability of healthcare systems.

April 29, 2025 • By investors.com

Regeneron stock plummeted 9% after the biotech company reported a significant revenue miss due to lower-than-expected sales of its eye drug Eylea. This major revenue miss dragged down the company's earnings, causing the stock to tumble on Tuesday.

April 29, 2025 • By ET Online

The provided text appears to be a collection of news headlines and advertisements from The Economic Times. The main news story that can be gleaned from the text is about the Pahalgam terrorist attack and India's potential response to Pakistan. Key points include: - A terrorist attack occurred in Pahalgam. - India is considering closing its airspace to Pakistani carriers amid rising tensions. - India has a "Cold Start" strategy, which is a swift strike plan in response to Pakistan's nuclear threats. - Prime Minister Modi chaired a high-level meeting to discuss the situation. - There are also mentions of other news stories, including business news, political developments, and sports updates. Overall, the text suggests heightened tensions between India and Pakistan, with India considering various responses to the terrorist attack and Pakistan's nuclear threats.

April 29, 2025 • By Verified Market Research

The Global Cultured Meat Market is projected to grow at a CAGR of 17.15% from 2024 to 2031, reaching USD 538.48 Million by 2031. The market was valued at USD 169.48 Million in 2023. Key drivers include rising demand for sustainable and ethical food sources, technological advancements in cellular agriculture, and increasing global investments and strategic partnerships. However, high production costs, regulatory uncertainty, and consumer acceptance barriers remain challenges. North America, Europe, and Asia-Pacific are expected to dominate the market, with key players including Eat Just, Inc., Mosa Meat, and Aleph Farms. The market is segmented by source, product type, and geography. Verified Market Research provides in-depth analysis and insights to help businesses understand the evolving market landscape.

April 29, 2025 • By Magnus Ölander, Daniel Rea Vázquez, Karsten Meier, Aakriti Singh, Amanda Silva de Sousa, Fabiola Puértolas-Balint, Milica Milivojevic, Lieke Mooij, Johanna Fredlund, Eduard Calpe Bosch, María Rayón Díaz, Moa Lundgren, Karin van der Wal, Shaochun Zhu, André Mateus, Bjoern O. Schroeder, Jeremy R. Lohman, Barbara S. Sixt

Researchers have identified over 60 compounds that can prevent the growth of Chlamydia trachomatis, a common bacterial pathogen, in cell cultures. These compounds are chemically diverse, non-toxic to human cells, and highly potent. Some compounds can block the development of C. trachomatis reversibly, while others can eradicate both established and persistent infections. The top molecules display broad activity against diverse Chlamydia strains and species. The most potent antichlamydial compound inhibits fatty acid biosynthesis via covalent binding to the active site of Chlamydia FabH, highlighting a possible way to selectively treat Chlamydia infections. The study used a combination of experimental and virtual screening to identify these compounds, and the results provide a promising starting point for the development of new, selective therapies against Chlamydia infections.

April 29, 2025 • By Ruonan Zhang, Tengfei Wang, Yu Cheng, Jiaxin Qiu, Dongsheng Jia, Hongyan Chen, Taiyun Wei, Xiao-Feng Zhang

Researchers have made a significant discovery about how the rice stripe mosaic virus (RSMV) interacts with its insect vector, the leafhopper Recilia dorsalis. The study found that RSMV triggers an autophagic response in leafhopper cells, which is a defense mechanism that helps to eliminate the virus. However, the virus has evolved a way to evade this response by using its M protein to disrupt the autophagy pathway. The researchers used a combination of techniques, including immunofluorescence microscopy, western blotting, and yeast two-hybrid assays, to investigate the interaction between RSMV and its insect vector. They found that the RSMV G protein interacts with the leafhopper's AMP-activated protein kinase (AMPK), which leads to the activation of autophagy. However, the RSMV M protein binds to the autophagy-related protein ATG14, disrupting the formation of autophagosomes and allowing the virus to evade the autophagic response. The study provides new insights into the mechanisms of virus-vector interactions and highlights the importance of autophagy in plant virus transmission. The findings could have significant implications for the development of strategies to control the spread of plant viruses, which are a major threat to global food security. Key findings: * RSMV triggers an autophagic response in leafhopper cells, which is a defense mechanism that helps to eliminate the virus. * The RSMV G protein interacts with the leafhopper's AMPK, leading to the activation of autophagy. * The RSMV M protein binds to ATG14, disrupting the formation of autophagosomes and allowing the virus to evade the autophagic response. * The study provides new insights into the mechanisms of virus-vector interactions and highlights the importance of autophagy in plant virus transmission.

April 29, 2025 • By Rui-Si Hu, Kui Gu, Muhammad Ehsan, Sayed Haidar Abbas Raza, Chun-Ren Wang

Researchers have developed a deep learning model called deepBCE-Parasite to predict linear B-cell epitopes (BCEs) in parasites. The model uses a Transformer-based architecture and achieved an accuracy of 81% and an AUC of 0.90 in both 10-fold cross-validation and independent testing. The model was trained on a dataset of 5,752 positive and 5,752 negative BCEs and was compared to traditional machine learning models, including SVM, RF, LGBM, and GNB. The results showed that deepBCE-Parasite outperformed the traditional models in predicting BCEs. The model was also applied to proteomic data from the liver fluke Fasciola hepatica, and the predicted BCEs were validated using dot-blot immunoassays. The study demonstrates the potential of AI in advancing epitope prediction in parasitology and provides a valuable tool for the development of epitope-based vaccines, therapeutic antibodies, and diagnostic applications.

April 29, 2025 • By Shihao Zhou, Qiyu Zhu, Minho Eom, Shilin Fang, Oksana M. Subach, Chen Ran, Jonnathan Singh Alvarado, Praneel S. Sunkavalli, Yuanping Dong, Yangdong Wang, Jiewen Hu, Hanbin Zhang, Zhiyuan Wang, Xiaoting Sun, Tao Yang, Yu Mu, Young-Gyu Yoon, Zengcai V. Guo, Fedor V. Subach, Kiryl D. Piatkevich

Citation: Zhou S, Zhu Q, Eom M, Fang S, Subach OM, Ran C, et al. (2025) A sensitive soma-localized red fluorescent calcium indicator for in vivo imaging of neuronal populations at single-cell resolut…

April 29, 2025 • By Cheng Zhong, Liping Zhong

A recent study published in PLOS explores the role of CHRM2 in osteogenic differentiation and its potential as a biomarker for osteoporosis (OP). The researchers used single-cell RNA sequencing to analyze cell type distributions between OP patients and healthy controls, finding an increase in M1 macrophages and regulatory T cells in OP patients. Functional enrichment analysis highlighted the involvement of regulatory T cells in OP pathogenesis. The study also identified CHRM2 as a key gene associated with oxidative stress. In vitro experiments demonstrated that CHRM2 knockdown enhanced osteogenic differentiation while suppressing cell proliferation. The findings suggest that CHRM2 plays a negative regulatory role in osteogenic differentiation and may serve as a diagnostic biomarker and therapeutic target for early-stage OP. The study provides new insights into the mechanisms of osteoporosis and the potential for personalized treatment strategies.

April 29, 2025 • By Karine Narbonne-Reveau, Andrea Erni, Norbert Eichner, Shobana Sankar, Surbhi Kapoor, Gunter Meister, Harold Cremer, Cédric Maurange, Christophe Beclin

Researchers have developed a new approach called AGO-APP to isolate and analyze active microRNAs (miRNAs) in specific cell types within tissues. Using this technique in the larval Drosophila central nervous system, they identified a module of miRNAs that regulate the transition from neural stem cells to neurons. The study found that these miRNAs work together to maintain neural stem cell identity and that their cooperative action allows for efficient targeting of entire gene networks. The findings provide strong evidence for the concept that miRNAs can control complex biological processes through additive, synergistic, or combinatorial interactions. The researchers used AGO-APP to purify Argonaute-bound miRNAs from neuroblasts, neurons, and glial cells in the Drosophila CNS. They then used bioinformatic tools to predict the target genes of these miRNAs and found that they targeted key genes involved in the transition from neuroblasts to neurons, as well as temporal patterning genes. The study's results suggest that the concerted action of several miRNAs allows for the silencing of a defined ensemble of genes involved in a specific biological process. This paves the way for the precise manipulation of entire gene networks through the control of miRNA activity. The AGO-APP approach represents a sensitive and reliable method for isolating all AGO-bound miRNAs in a single step and can be used to study the functional significance of miRNAs in various biological processes. Overall, the study provides new insights into the role of miRNAs in regulating gene expression and cellular processes, and it has implications for our understanding of the complex interactions between miRNAs and their target genes. The findings also highlight the potential of the AGO-APP approach for studying miRNA function in various biological contexts.

April 29, 2025 • By investors.com

Regeneron stock plummeted 10% after the biotech company reported a significant revenue miss due to lower-than-expected sales of its eye drug Eylea. The earnings report was affected by the poor performance of Eylea, causing Regeneron's stock to tumble on Tuesday.

April 29, 2025 • By Koray Köse, Forbes Councils Member, Koray Köse, Forbes Councils Member https://www.forbes.com/councils/forbestechcouncil/people/koraykose/

The article discusses the current state of global trade, technology, and power dynamics, which are undergoing a significant shift. The author, Koray Köse, argues that the world is experiencing a "reset phase" as it transitions from the 5th Kondratiev cycle (digital revolution) to the 6th cycle (AI, quantum computing, space, and biotech). This shift is characterized by multipolar chaos, with new power centers like China, Russia, and the EU challenging the existing global frameworks. The article highlights the importance of understanding the sensitivity and fragility of global trade, as well as the need for strategic and informed decision-making to navigate the current landscape. The author notes that tariffs are being used as a tool to reset the global framework, but warns that mishandling them can cause significant disruptions to supply chains and financial systems. The article also discusses the concept of "friendshoring," where companies are shifting their supply chains to more stable and secure regions, such as Mexico and Canada. The author advises businesses to identify their core drivers (people, process, or technology) and rebuild in a region with relative stability, taking short-term hits but avoiding long-term collapse. Overall, the article emphasizes the need for assertive, educated, and risk-managing leaders to navigate the current storm and position themselves for success in the new global landscape. It also highlights the importance of understanding the convergence of geopolitics, economics, and technology, and the need for agile and adaptive supply chains to handle the complexity of operating in multiple geopolitical blocs.

April 29, 2025 • By Kate Kenny, Professor of Business and Society, University of Galway

Whistleblowers play a crucial role in holding governments and corporations accountable, but speaking up can come at a cost. Many face retaliation, job loss, or legal threats, making whistleblowing risky and challenging. In the US, a Trump administration executive order threatens to strip thousands of federal workers of their whistleblower protection rights. However, research shows that insiders who successfully sound the alarm often do so with help from allies who can amplify their message and shield them from retaliation. Examples include Facebook employee Frances Haugen, who teamed up with Wall Street Journal reporter Jeff Horwitz to expose the social media platform's exploitation of teenagers. Theranos whistleblower Erika Cheung received critical advice from a lawyer, which helped her disclose to a regulator and avail of whistleblower protection. Amazon manager Chris Smalls was supported by colleagues and nonprofit groups after being fired for speaking out about COVID-19 risks. Organizing whistleblowing allies involves strategy, and some groups have become experts in this domain. The US Government Accountability Project uses an "information matchmaking" approach, treating whistleblower protection and support efforts as holistic campaigns. Whistleblower allies can help tip the balance of power, bringing public opinion to bear on employers or governments bent on reprisal. While there is no magic bullet, collective effort and support from allies can make a significant difference in the outcome of whistleblowing cases.

April 29, 2025 • By Moleculin Biotech, Inc.

Moleculin Biotech, Inc. presented research at the American Association for Cancer Research (AACR) Annual Meeting 2025, showing that Annamycin, a next-generation anthracycline, can work synergistically with various FDA-approved anticancer therapies. The study found that Annamycin, in both its non-liposomal and liposomal forms, demonstrated efficacy in combination with approved drugs, including azacitidine, cytarabine, and gemcitabine, in treating leukemia and solid tumors, such as sarcoma and pancreatic cancer. These findings suggest that Annamycin may have potential applications in combination therapies for hard-to-treat cancers. Moleculin's CEO, Walter Klemp, stated that the research supports the company's view that Annamycin could be used to treat a range of cancers, including solid tumors, and may be attractive to future partners. The company is currently developing Annamycin for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

April 29, 2025 • By Alexander Cope

Overwatch 2 has launched a brand new game mode called Stadium, and it is unlike any mode that's come before in the long-running hero shooter. In this mode, two teams of five players compete in seven …

April 29, 2025 • By finance.yahoo.com

Biohaven has secured a funding deal worth up to $600m from Oberland Capital Management. The financing provides non-dilutive capital as the biotech awaits an FDA decision on its prodrug, troriluzole, for spinocerebellar ataxia (SCA). This funding will support Biohaven's preparations for a potential US launch of the treatment.

April 29, 2025 • By Jenna Philpott

Biohaven has secured a non-dilutive funding deal worth up to $600m from Oberland Capital Management. The deal will provide capital as Biohaven awaits an FDA ruling on its spinocerebellar ataxia drug, troriluzole. The financing comes in the form of a note purchase agreement, with the first tranche of $250m scheduled to be funded by April 30. The second tranche of $150m is contingent on FDA approval, and a third tranche of $200m may be used for strategic acquisitions. Biohaven's shares closed 9.6% higher after the announcement. The company is positioning the new funding to accelerate commercial planning and advance its pipeline, which includes CNS-targeting therapies. Troriluzole is being evaluated for spinocerebellar ataxia, a rare neurodegenerative disorder with limited treatment options. The FDA granted the application priority review in February 2025, with a final decision expected in Q3 2025.

April 29, 2025 • By Dianthus Therapeutics, Inc.

Dianthus Therapeutics, a clinical-stage biotechnology company, announced its participation in two upcoming investor events. The company, which focuses on developing antibody complement therapeutics for severe autoimmune diseases, will have webcasts of its presentations available on its website. Dianthus is led by experienced biotech and pharma executives and aims to deliver transformative medicines for people with autoimmune and inflammatory diseases.